‘Pharma must exit generics-only model’

The Story in Brief

Industry leaders from Sun Pharma, Biocon and Glenmark called on India to move beyond generic medicines and invest in innovative drug development, speaking at the Indian Foundation for Quality Management's Third Annual Symposium on Monday, 5 October. Sun Pharma Executive Chairman Dilip Shanghvi said the sector has reached a scale where companies can fund innovation and launch products globally. Biocon’s Kiran Mazumdar-Shaw stressed the need for a credible ecosystem built around quality, research and regulatory excellence, while Glenmark’s Glenn Saldanha said the next decade is critical for India to become an innovation-led pharmaceutical powerhouse.

Pharma sector urged to shift from scale to trust for global edge

Separately, a joint Grant Thornton Bharat-Ficci report released the same day said India’s next growth phase depends on quality, regulatory trust and supply-chain resilience, not just cost and scale. It noted data-integrity issues featured in about 60 per cent of FDA warning letters involving Indian pharma sites in FY2025, against 15 per cent globally. The report said the pharmaceutical PLI scheme has attracted Rs 45,774 crore of investment and generated over 113,000 jobs as of March 2026.

Update, 7 October: Economic Times and Forbes India report Kiran Mazumdar-Shaw’s call for faster regulatory reforms and Shanghvi’s comment that government schemes will accelerate the transition. Forbes India adds that Sun’s acquisition of Organon will help it register products faster globally. A separate Times of India report on Granules India’s Rs 2,000 crore investment plan for complex generics and oncology concerns a different company and is not part of the symposium coverage.

Update, 8 October 2026: Economic Times and Forbes India report additional remarks from the same IFQM symposium, including Kiran Mazumdar-Shaw’s call for faster regulatory reforms and Dilip Shanghvi’s comment that the government’s schemes will accelerate the transition. Forbes India adds that Sun’s acquisition of Organon will help it register products faster globally. A separate story from The Times of India reports Granules India’s Rs 2,000 crore investment plan for complex generics and oncology, which is a different company and not part of the symposium coverage.

Indian Opinion Analysis

Business Standard quotes a Grant Thornton-Ficci report that frames India's pharmaceutical future around quality, regulatory trust and supply-chain resilience, flagging that data-integrity issues featured in about 60 per cent of FDA warning letters for Indian sites in FY2025, against 15 per cent globally. The Hindu Business Line, Economic Times and Forbes India coverage of the IFQM symposium leads with industry leaders’ call to move beyond generics toward innovation, with Forbes India detailing Sun’s Organon acquisition and Chinese comparisons, while Medical Dialogues runs near-identical symposium copy without the report coverage. The critical-reform emphasis of the report, absent from the symposium-only stories, balances the largely upbeat industry messaging with a concrete regulatory weakness. India exports drugs worth $30.5 billion and ranks third globally by volume, the report states.

Coverage: 9 sources, 8 neutral, 1 sensationalist


Sources (9): business-standard.com (neutral report), thehindubusinessline.com (neutral report), economictimes.indiatimes.com (neutral report), forbesindia.com (sensationalist), timesofindia.indiatimes.com (neutral report), economictimes.indiatimes.com (2) (neutral report), economictimes.indiatimes.com (3) (neutral report), medicaldialogues.in (neutral report), economictimes.indiatimes.com (4) (neutral report)

This brief was synthesised by AI from the 9 sources linked above, so one read covers every framing they carry. Methodology and corrections.

Ask their opinion on this story
They have read this article, our coverage, and the web.
AI simulations of historical figures. Responses are generated from the historical record, not authentic statements.

0 Votes: 0 Upvotes, 0 Downvotes (0 Points)

Share your opinion

Sign in to comment

Comments are open to readers with an Indian Opinion account. We email you a 6-digit code; there is no password.

Sign in to comment

Loading Next Post...
Search Trending
Ask their opinion
Loading

Signing-in 3 seconds...

Signing-up 3 seconds...

All fields are required.